PRF Technologies Ltd. (PRFX)
NASDAQ: PRFX · Real-Time Price · USD
0.8993
-0.0462 (-4.89%)
Jan 22, 2026, 1:04 PM EST - Market open
PRF Technologies Employees
As of December 31, 2024, PRF Technologies had 6 total employees, including 2 full-time and 4 part-time employees. The number of employees decreased by 1 or -14.29% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$681,000
Market Cap
3.52M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 6 | -1 | -14.29% | 2 | 4 |
| Dec 31, 2023 | 7 | 1 | 16.67% | 7 | 0 |
| Dec 31, 2022 | 6 | 2 | 50.00% | 6 | 0 |
| Dec 31, 2021 | 4 | 2 | 100.00% | 4 | 0 |
| Dec 31, 2020 | 2 | - | - | 1 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Universe Pharmaceuticals INC | 225 |
| China Pharma Holdings | 224 |
| IM Cannabis | 95 |
| Biofrontera | 93 |
| Flora Growth | 75 |
| Sunshine Biopharma | 52 |
| cbdMD | 42 |
| RedHill Biopharma | 35 |
PRFX News
- 2 days ago - PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy - GlobeNewsWire
- 6 days ago - PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push - Benzinga
- 6 days ago - PainReform Ltd. Changes Name to PRF Technologies Ltd. - GlobeNewsWire
- 10 days ago - PainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies - GlobeNewsWire
- 17 days ago - PainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market - GlobeNewsWire
- 23 days ago - BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week - PRNewsWire
- 6 weeks ago - PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities - GlobeNewsWire
- 7 weeks ago - PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy - GlobeNewsWire